#USA #San Francisco #J.P. Morgan #Field Medical #PFA Technology

Field Medical Inc. to Present at the 44th Annual J.P. Morgan Healthcare Conference

Field Medical Inc., an innovative player in the field of medical technology, has announced its participation in the 44th Annual J.P. Morgan Healthcare Conference, scheduled for January 15, 2026. The company's founder, Dr. Steven Mickelsen, is set to present at the event, highlighting the firm’s advancements in pulsed field ablation (PFA) technology. This cutting-edge platform is aimed at transforming the treatment landscape for cardiac arrhythmias, specifically targeting ventricular tachycardia (VT) and atrial fibrillation (AF).

The J.P. Morgan Healthcare Conference is one of the most significant events in the healthcare industry, bringing together leading experts, innovators, and investors to explore the future of healthcare solutions. Field Medical's participation underscores its growth and commitment to enhancing patient care through advanced technology. Dr. Mickelsen’s presentation will include a comprehensive overview of the company, its flagship product, the FieldForce™ Ablation System, and its clinical progress in the treatment of complex cardiac conditions.

Innovations in Technology

The FieldForce™ Ablation System represents a next-generation approach to cardiac ablation, leveraging a unique pulsed field ablation technique to create transmural lesions, which are crucial for effectively treating arrhythmias. The system combines a focused catheter design with proprietary FieldBending™ energy, delivering precise and efficient ablation while minimizing collateral tissue damage. This innovative approach could significantly enhance outcomes for patients with complex arrhythmias, making it a vital asset for cardiology professionals.

Clinical Trials and Future Plans

During the presentation, Dr. Mickelsen will also discuss the recent advancements in clinical trials, highlighting the Field-PULSE AF study and future pivotal trials focused on VT. The company’s dedication to rigorous clinical research has earned it recognition, including the Breakthrough Device Designation from the FDA, which facilitates expedited development for devices demonstrating significant benefits over existing options. This designation is particularly crucial as Field Medical aims to solidify its position in the fast-evolving market of cardiac arrhythmia treatments.

In 2024, Field Medical was granted access to the FDA's TAP Pilot Program, focusing on its treatment indication for ventricular tachycardia. This program is designed to foster innovative designs and new technologies in medical devices, ensuring that healthcare solutions meet the highest standards of efficacy and safety. Moreover, the VCAS trial results were published in the prestigious journal Circulation in October 2025, further establishing the company’s credibility in the medical community.

Meeting Opportunities at the Conference

Field Medical’s leadership team will be available for meetings during the conference, providing opportunities for potential investors and partners to engage with the team and discuss collaboration or investment opportunities. Interested parties can arrange a meeting by reaching out via email at the provided contact information. This presents a unique chance to learn more about the transformative potential of Field Medical's technology and its commitment to revolutionizing cardiac care.

Field Medical Inc. is dedicated to advancing medical technology for treating complex cardiac conditions, ensuring that patients receive the best possible care backed by innovative solutions. The journey towards improving cardiac care continues as the company showcases its capabilities at one of the most prestigious healthcare conferences in the world.

For more information about Field Medical and its innovations, individuals can visit their website at www.fieldmedicalinc.com and follow them on LinkedIn, X, and YouTube for the latest updates on their groundbreaking work in healthcare technology.